Novartis receives EU approval for Cosentyx label update

ZURICH (Reuters) - Novartis said that the Committee for Medicinal Products for Human Use (CHMP) has approved a label update for Cosentyx (secukinumab), the first interleukin-17A (IL-17A) approved to treat psoriasis.

The label update includes 52 week data from the CLEAR study demonstrating the long-term superiority of Cosentyx versus Stelara (ustekinumab) in psoriasis, a common, non-contagious, auto-immune disease, the Swiss pharmaceutials company said on Thursday.

(Reporting by Silke Koltrowitz)

Related News

Qatar Airways says joins major Middle East carriers in lifting of U.S. laptop ban

Jul 6, 2017

US-USA-AIRLINES-ELECTRONICS:Qatar Airways says joins major Middle East carriers in lifting of U.S. laptop ban

NBA star LeBron James' L.A. home vandalized with racial slur

Jun 1, 2017

US-CALIFORNIA-RACE-LEBRON-JAMES:NBA star LeBron James' L.A. home vandalized with racial slur

U.S. communications agency considers helping in probe of Jewish center threats

Mar 2, 2017

US-THREATS-FCC:U.S. communications agency considers helping in probe of Jewish center threats

Must Read

Qatar Airways says joins major Middle East carriers in lifting of U.S. laptop ban

Jul 6, 2017

US-USA-AIRLINES-ELECTRONICS:Qatar Airways says joins major Middle East carriers in lifting of U.S. laptop ban

NBA star LeBron James' L.A. home vandalized with racial slur

Jun 1, 2017

US-CALIFORNIA-RACE-LEBRON-JAMES:NBA star LeBron James' L.A. home vandalized with racial slur

U.S. communications agency considers helping in probe of Jewish center threats

Mar 2, 2017

US-THREATS-FCC:U.S. communications agency considers helping in probe of Jewish center threats

About Us

Travel Leisure Mag is New York City’s travel and lifestyle online magazine with the vision of creating a unique blend of valuable and quality travel experience to the readers. We trust that you will enjoy this experience.

Contact us: sales@travelleisuremag.com